Alexion Pharmaceuticals
American healthcare company / From Wikipedia, the free encyclopedia
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
Company type | Subsidiary |
---|---|
Nasdaq: ALXN | |
Industry | Pharmaceutical industry |
Founded | 1992; 32 years ago (1992) |
Founder | Leonard Bell |
Headquarters | Boston, Massachusetts, U.S. |
Key people | Leonard Bell (Chairman) Ludwig N. Hantson (CEO) |
Products | Eculizumab (Soliris) Ravulizumab (Ultomiris) Asfotase alfa (Strensiq) Sebelipase alfa (Kanuma) Andexanet alfa (Andexxa) |
Revenue | US$6.069 billion (2020) |
US$603 million (2020) | |
Total assets | US$18.103 billion (2020) |
Total equity | US$11.651 billion (2020) |
Number of employees | 2,525 (2020) |
Parent | AstraZeneca |
Website | www |
Footnotes / references [1] |
Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa), used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.[1]
With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.[2]